Expression Of P95HER2 And Its Clinical Value In HER-2 Positive Breast Cancer Patients

Objective:To study the expression of P95HER-2 in HER-2 positive breast cancer patients and its relationship with clinicopathologic features and prognosis of breast cancer,and to analyze the relationship between the expression of P95HER-2 and the curative effect of HER-2 positive breast cancer treated with Trastuzumab.Methods :paraffin-embedded blocks and clinical data of 82 patients with HER-2 positive breast cancer were collected from June 2012 to July 2013.The expression of P95HER2 was detected by Immunohistochemistry(IHC).The difference between the positive and negative groups was compared by Chi-square test,and the Disease Free Survival(DFS)and Overall Survival(OS)were compared between the two groups by Kaplan-Meier method,Cox multivariate analysis of prognostic factors.Results : The positive rate of P95HER2 was 24.4% in 82 HER-2 positive breast cancer specimens and 2.5% in adjacent tissues.The expression of P95HER2 was not correlated with age,family history,tumor size,TNM stage and axillary lymph node metastasis(p > 0.05).The expression of Ki-67 was correlated with the hormone receptor status,the level of KI-67 and the status of nerve invasion.The factors influencing OS in patients with Her-2 positive breast cancer are: Tumor Thrombus in vessels,nerve invasion and expression of P95HER2.In Cox multivariate analysis of DFS and Os in HER-2 positive breast cancer patients,the expression of P95HER2 was a risk factor for DFS.There was no correlation between the expression of P95HER2 and Trastuzumab in HER-2 positive breast cancer patients.Conclusion : In HER-2 positive breast cancer patients,the expression of P95HER-2 was correlated with hormone receptor status,Ki-67 expression,nerve invasion and overall survival,however,larger studies are needed to confirm the association with different prognostic factors and their impact on survival.There was no correlation with the efficacy of Trastuzumab in HER-2 positive breast cancer.